cambridge.org/cty

Original Article

Cite this article: Gao N, Lv Y, Cui Y, Wang P, and He X (2024) Bosentan in the treatment of persistent pulmonary hypertension in newborns: a systematic review and metaanalysis. *Cardiology in the Young* **34**: 1334–1341. doi: 10.1017/S1047951123004456

Received: 22 September 2023 Revised: 2 December 2023 Accepted: 19 December 2023 First published online: 8 February 2024

Keywords:

bosentan; persistent pulmonary hypertension; newborn

Corresponding author:

Y. Cui; Email: cuiyanbin_cyb@163.com

© The Author(s), 2024. Published by Cambridge University Press.



Bosentan in the treatment of persistent pulmonary hypertension in newborns: a systematic review and meta-analysis

Ning Gao¹, Yuanyuan Lv², Yanbin Cui³⁽⁰⁾, Pengchun Wang¹ and Xin He¹

¹Neonatology Department, Baoding No.1 Central Hospital, Baoding, China; ²Infection control office, Baoding No.1 Central Hospital, Baoding, China and ³Emergency Department, Baoding No.3 Central Hospital, Baoding, China

Abstract

Background: Persistent pulmonary hypertension of the newborn is a life-threatening condition that affects about 1-2 per 1,000 live births worldwide. Bosentan is an oral dual endothelin receptor antagonist that may have a beneficial effect on persistent pulmonary hypertension of the newborn by reducing pulmonary vascular resistance and improving oxygenation. However, its role in persistent pulmonary hypertension of the newborn remains unclear. Objectives: To systematically evaluate the efficacy and safety of bosentan as an adjuvant therapy for persistent pulmonary hypertension of the newborn in newborns. Methods: We searched six English and two Chinese databases from their inception to 1 January 2023 following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We included randomised controlled trials and retrospective studies that compared bosentan with placebo or other drugs for persistent pulmonary hypertension of the newborn in newborns. We performed a metaanalysis using random-effects models and assessed the risk of bias and heterogeneity in the included studies. Results: We included 10 studies with a total of 550 participants. Bosentan significantly reduced the treatment failure rate (relative risk = 0.25, P < 0.001), pulmonary artery pressure (mean difference = -11.79, P < 0.001), and length of hospital stay (mean difference = -1.04, P = 0.003), and increased the partial pressure of oxygen (mean difference = 10.02, P < 0.001) and blood oxygen saturation (SpO2) (mean difference = 8.24, P < 0.001) compared with a placebo or other drugs. The occurrence of adverse reactions was not significantly different between bosentan and a placebo or other drugs. Conclusions: Bosentan is effective in the treatment of persistent pulmonary hypertension of the newborn but adverse reactions such as abnormal liver function should be observed when using it.

Persistent pulmonary hypertension of the newborn is a life-threatening condition that affects about 1–2 per 1,000 live births worldwide.¹ It occurs when pulmonary vascular resistance remains abnormally elevated after birth, which causes an abnormal transition from foetal circulation to normal "adult" circulation type, resulting in the right-to-left shunting of blood at the level of the ductus arteriosus and/or foramina ovale. This leads to severe hypoxaemia, acidosis, and multiorgan dysfunction.² The main goal of persistent pulmonary hypertension of the newborn treatment is lowering pulmonary vascular resistance and improving oxygenation, which can be achieved by various pharmacological and non-pharmacological interventions. However, the optimal treatment strategy for persistent pulmonary hypertension of the newborn remains controversial and challenging.³

One of the key pathophysiological mechanisms involved in persistent pulmonary hypertension of the newborn is the dysregulation of endothelin-1, a potent vasoconstrictor and pro-inflammatory mediator that is primarily expressed in the lungs.⁴ The effects of endothelin-1 are exerted by binding to two types of receptors: endothelinA receptor and endothelinB receptor. The former are located on vascular smooth muscle cells and mediate vasoconstriction, while the latter are located on endothelial cells and mediate vasodilation through nitric oxide production.⁵ In persistent pulmonary hypertension of the newborn, there is increased endothelin-1 expression and an imbalance of endothelin-1 receptor expression in the lungs, with decreased endothelinB receptor protein synthesis in pulmonary artery endothelial cells.⁶ This leads to increased pulmonary vascular resistance and reduced nitric oxide availability.⁷

Bosentan is an oral dual endothelin receptor antagonist that can block both endothelinA and endothelinB receptors, thereby inhibiting the vasoconstrictive and pro-inflammatory effects of endothelin-1.⁸ Bosentan is effective and safe for treating pulmonary arterial hypertension in adults and children.^{9,10} However, its role in persistent pulmonary hypertension of the newborn is still unclear. Studies have suggested that bosentan may have a beneficial effect on persistent pulmonary hypertension of the newborn by reducing pulmonary vascular resistance, improving oxygenation and preventing the development of chronic lung disease.^{11,12} However, other



studies have failed to demonstrate any additive effect of bosentan on top of inhaled nitric oxide or other therapies.^{13,14} Moreover, the optimal dose and duration of bosentan treatment for persistent pulmonary hypertension of the newborn remain unknown.

Accordingly, we conducted a systematic review and metaanalysis to evaluate the efficacy and safety of bosentan as an adjuvant therapy for persistent pulmonary hypertension of the newborn in newborns. We compared bosentan with a placebo and other drugs such as sildenafil and iloprost or inhaled NO. Sildenafil is a phosphodiesterase type 5 inhibitor that enhances nitric oxidemediated vasodilation.¹⁵ Iloprost is a prostacyclin analogue that stimulates adenylate cyclase and increases cyclic adenosine monophosphate, leading to vasodilation and anti-inflammatory effects.¹⁶ Inhaled nitric oxide is a selective pulmonary vasodilator that activates soluble guanylate cyclase and increases cyclic guanosine monophosphate, resulting in smooth muscle relaxation.¹⁷ These drugs have different mechanisms of action and potential side effects, and their comparative efficacy and safety for persistent pulmonary hypertension of the newborn treatment are not well established.¹⁸ Finally, we hypothesised that bosentan could reduce the treatment failure rate, pulmonary artery pressure, and length of hospital stay, and increase the partial pressure of oxygen and blood oxygen saturation compared with a placebo or other drugs.

Materials and methods

Literature search strategy

In adherence to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we conducted a systematic search across various databases in both English and Chinese. We systematically searched English databases including PubMed, Web of Science, the National Library of Medicine, Scopus, Embase, and ClinicalTrials.gov for literature on the use of Bosentan in the treatment of persistent pulmonary hypertension of the newborn, while the Chinese databases encompassed the China National Knowledge Infrastructure and Wanfang Data. Searches were made from the inception date of each database up to January 1, 2023.

Our search strategy involved the use of a combination of subject words and free words. For the English databases, the keywords included "Bosentan," "Bosentan hydrate," "Ro47-0203," "newborn," "infant," "persistent pulmonary hypertension," "persistent foetal circulation," and "persistent pulmonary hypertension of the newborn." Boolean operators (AND, OR) were utilised to refine the search, and adjustments were made to the strategy based on the specific requirements of each database.

In the Chinese databases (China National Knowledge Infrastructure and Wanfang Data), the keywords used were the Chinese equivalents of "Bosentan," "newborn," and "persistent pulmonary hypertension." No language or date restrictions were applied in our search strategy. This approach aimed to ensure a comprehensive and inclusive retrieval of relevant studies across all the selected databases.

Inclusion and exclusion criteria

The inclusion criteria applied to the literature were as follows. (1) Study type: randomised controlled trials or retrospective studies published in Chinese or English; (2) study participants: newborns diagnosed with persistent pulmonary hypertension of the newborn according to guidelines established by the American Heart Association and the American Thoracic Society;¹⁹ (3) interventions:

the control group received a placebo or other drugs or other drugs combined with bosentan, while the experimental group received bosentan or bosentan combined with other drugs; and (4) outcome indicators: treatment failure rate, pulmonary artery pressure (mmHg), partial pressure of oxygen (PaO₂, kPa), and blood oxygen saturation (SaO₂, %), length of hospital stay and the occurrence of adverse reactions. The exclusion criteria applied to the literature were as follows. (1) Literature with incomplete data that could not be utilised or from which valid data could not be extracted; (2) animal/ in vitro cell experiments; and (3) case investigations or review studies.

Literature screening and data extraction

The literature was screened independently by two investigators. The initial screening was performed according to the title and abstract; then, secondary screening was performed by reading the full text according to the inclusion and exclusion criteria. In case of any disagreements, the opinions of a third investigator were solicited and discussed to reach a consensus. After the literature screening, data were extracted independently by two investigators, including the first author, year of publication, study region, study type, sample size, and the risk factors included in each study. Any discrepancies or missing data were resolved by contacting the original authors or consulting the third investigator.

Literature quality evaluation

The Cochrane Collaboration's tool for assessing the risk of bias²⁰ was utilised to evaluate the quality of the included randomised controlled trials, including (1) random sequence generation; (2) allocation concealment; (3) blinding of participants and personnel; (4) blinding of the outcome assessment; (5) incomplete outcome data; (6) selective reporting outcome indicators; and (7) other bias. For the included literature, a judgment of "yes" (low risk), "no," (high risk) or "unclear" (lack of relevant information or uncertain bias) was made for the above 7 items. Literature rated as reflecting a high or low risk of bias for any one item was categorised as having a high or low risk of bias, respectively. Otherwise, the literature was categorised as having an unclear risk of bias.

The finally included regression studies were evaluated for quality in three aspects: selection, comparability and exposure or outcome using the Newcastle–Ottawa Scale. A total of 9 points were set for this scale, and 1 point was scored if the scoring conditions were met. Studies with scores < 5 were classified as low-quality studies and those with scores \geq 5 were classified as high-quality studies. Studies with a Newcastle–Ottawa Scale score < 5 were not included in the meta-analysis.²¹

Statistical analysis

Meta-analysis was performed using Revman5.3 software. The measurement data used the mean difference, while the count data used relative risk as the effect indicator. Effect sizes were expressed as point estimates and 95% confidence intervals, and statistical analysis was performed based on changes before and after treatment. For the heterogeneity test, test was used to judge the degree of heterogeneity, with < 50% or P > 0.1 indicating the homogeneity of the included literature, which was analysed using the fixed-effects model (Mantel-Haenszel); > 50% or P \leq 0.1 indicated a degree of heterogeneity among the included studies, which was analysed using the random-effects model (DerSimonian-Laird). Furthermore, a leave-one-out method was




Figure 1. Flow chart of literature screening.

used for sensitivity analysis, and a descriptive analysis was conducted for studies where results could not be combined. The test level of the meta-analysis was set at $\alpha = 0.05$.

Results

Literature search results

In this study, a total of 1,640 literature studies were collected through database retrieval. After initial screening and based on the inclusion and exclusion criteria, 10 studies were finally included in the meta-analysis.^{2,22-30} Among them, 6 were in English^{2,22-26} and 4 were in Chinese.^{27–30} The literature screening flow chart is shown in Figure 1.

Basic characteristics of the included literature

The 10 pieces of literature finally included were published from 2012 to 2021, including 9 randomised controlled studies and 1 retrospective study.²³ One study was conducted in Europe,² and the remaining studies were conducted in Asia, of which 4 were conducted in China.²⁷⁻³⁰ A total of 550 samples were included, including 277 in the experimental group and 273 in the control group. The basic characteristics of the included literature are shown in Table 1.

Quality evaluation of included studies

The 9 included randomised controlled trial studies were all conducted using a randomised method. Among them, 4 studies^{2,22,24,25} achieved allocation concealment, blinding of participants and personnel, blinding of the outcome assessment, complete outcome data, no selective reporting of study results, and no other bias; accordingly, they were considered high-quality studies with a low risk of bias. The remaining 3 randomised controlled trial studies²⁷⁻²⁹ achieved complete outcome data and no selective reporting of study results, but there may have been other risks of bias; as such, they were considered to be medium-quality studies. The Newcastle–Ottawa Scale score of the retrospective study was 7, indicating a high-quality study.

Meta-analysis results

Treatment failure rate

Treatment failure rates were reported in 7 studies.^{2,22,26-30} Due to the homogeneity among the studies ($I^2 = 0\%$, P = 0.71), a fixedeffects model was used for the meta-analysis. The results showed that the treatment failure rate in the experimental group was lower than in the control group, with a statistically significant difference (relative risk = 0.25, 95% confidence interval: 0.14–0.44, standardised mean difference (Z-score) = 4.74, P < 0.001) as shown in Figure 2.

Table 1. Basic characteristics of selected studies

				Num	ber of cases	Intervention me	thod		Male	/Female (n)	Gestation	l Age (weeks) Birth Weight (g)		Literature		
Literature included	Publication year	Region	Study type	Control Group	Experimental Group	Control Group	Experimental Group	Route of administration	Control Group	Experimental Group	Control Group	Experimental Group	Control Group	Experimental Group	Outcome Indicators	Quality Evaluation
Mohamed ²²	2012	Asia	а	23	24	Placebo (equal volume of diluent)	Bosentan (1mg/kg bid)	Orogastric tub	12/11	10/14	38.8 ± 1.6	39.7 ± 1.8	3478.3 ± 602	3498.1 ± 512	1	High
Steinhorn ²	2016	Europe	а	8	13	Placebo (equal volume of diluent)	Bosentan (2mg/kg bid)	Nasogastric tub	2/6	4/9	38.6 ± 2.0	39.2 ± 2.1	3200 ± 500	3400 ± 500	1,5	High
Maneenil ²³	2018	Asia	b	21	19	Inhaled Nitric Oxide + Bosentan	Bosentan (1mg/kg)	Orogastric tube	-	-	-	-	3115 ± 543	2996 ± 931	5	High
Fatima ²⁴	2018	Asia	а	50	50	Sildenafil (2mg/kg tid)	Bosentan + Sildenafil (1mg/kg bid + 2mg/kg tid)	Oral	25/25	30/20	-	-	-	-	5	High
Farhangdoust ²⁵	2020	Asia	а	25	15	Sildenafil (0.4mg/kg)	Bosentan (1mg/kg)	Per gavage every 12 h	8/17	11/4	33.5 ± 0.6	33.5 ± 1	2108 ± 143.5	2174 ± 144.2	5	High
Vijay Kumar ²⁶	2021	Asia	а	15	25	Sildenafil (2mg/kg)	Bosentan + Sildenafil (1mg/kg bid + 2mg/kg)	Nasogastric tube or oral	2/13	12/13	-	-	2650 ± 302	2770 ± 240	1,2	High
Wang Wanli ²⁷	2019	Asia	а	47	47	Levocarnitine (50 ~ 100mg/ kg tid)	Bosentan (2mg/kg bid)	Nasogastric tube or oral	25/22	26/21	-	-	3400 ± 900	3500 ± 1200	1,2	Medium
Li Guanghong ²⁸	2020	Asia	а	21	21	Milrinone (50µg/kg/min)	Bosentan + Milrinone (1mg/kg q 12h + 50µg/kg/ min)	Oral and intravenous pumping	12/9	11/10	-	-	2780 ± 530	2770 ± 490	1,2,3,4	Medium
Li Kui ²⁹	2021	Asia	а	19	19	Milrinone (75µg/kg/min)	Bosentan + Milrinone (1mg/kg q 12h + 75µg/kg/ min)	Oral and intravenous pumping	9/10	10/9	38.6 ± 0.5	38.4 ± 0.6	2978.5 ± 191	2978.5 ± 181	1,2,3,4	Medium
Wang Shuangshuang ³⁰	2021	Asia	а	44	44	Treprostinil (10 ~ 15ng/kg/ min)	Bosentan + Treprostinil (2mg/kg bid + 10 ~ 15ng/ kg/min)	Oral and intravenous pumping	27/17	22/22	35.9 ± 5.0	34.3 ± 4.7	2910 ± 560	2860 ± 510	1,3,4	High

a = Randomised controlled trial, b = Retrospective study.

	Experim	ental	Contr	ol		Risk Ratio			Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	Year		M-H, Fixe	d, 95% CI		
Mohamed 2012	3	24	12	15	30.8%	0.16 [0.05, 0.46]	2012		-			
Steinhorn 2016	1	13	0	8	1.3%	1.93 [0.09, 42.35]	2016	-				_
Wang 2019	1	47	6	47	12.5%	0.17 [0.02, 1.33]	2019		•	-		
Li 2020	1	21	5	21	10.4%	0.20 [0.03, 1.57]	2020		•	-		
Li 2021	1	19	6	19	12.5%	0.17 [0.02, 1.26]	2021		•	-		
Vijay Kumar 2021	2	25	2	15	5.2%	0.60 [0.09, 3.83]	2021	-	•			
Wang 2021	4	44	13	44	27.2%	0.31 [0.11, 0.87]	2021		-			
Total (95% CI)		193		169	100.0%	0.25 [0.14, 0.44]			•			
Total events	13		44									
Heterogeneity: Chi ² =	3.75, df = 1	6 (P = 0	.71); I ² = I	0%				0.01 0.	1 4		10	100
Test for overall effect:	Z= 4.74 (F	o < 0.00	001)						perimental	control	10	100

Figure 2. Forest plot of treatment failure rate.

	Experimental			Control			Mean Difference			Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	Year		IV, Fixed	, 95% CI		
Wang 2019	-27.72	18.04	47	-13.86	17.31	47	18.3%	-13.86 [-21.01, -6.71]	2019					
Li 2020	-16	11.44	21	-10	11.17	21	20.0%	-6.00 [-12.84, 0.84]	2020		-			
Li 2021	-33.89	7.13	19	-21.04	7.51	19	43.1%	-12.85 [-17.51, -8.19]	2021		-			
Vijay Kumar 2021	-51.09	9.76	25	-37.58	11.75	15	18.7%	-13.51 [-20.58, -6.44]	2021					
Total (95% CI)			112			102	100.0%	-11.79 [-14.85, -8.73]			•			
Heterogeneity: Chi ² = Test for overall effect:		•								-100	-50 0 experimental	control	50	100

Figure 3. Forest plot of the decrease in pulmonary artery pressure.

	Expe	erimen	tal	C	ontrol			Mean Difference			Me	an Differend	e	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year		IV, R	andom, 95%	CI	
Li 2020	26.1	4.72	21	19.6	4.57	21	34.0%	6.50 [3.69, 9.31]	2020			-		
Li 2021	19.38	4.91	19	5.48	3.44	19	34.3%	13.90 [11.20, 16.60]	2021			-		
Wang 2021	36.12	8.55	44	26.54	8.28	44	31.7%	9.58 [6.06, 13.10]	2021			-		
Total (95% CI)			84			84	100.0%	10.02 [5.45, 14.58]				•		
Heterogeneity: Tau ² = Test for overall effect					= 0.00	009); I²	= 86%			-100	-50 experime	0 ental contro	50	100

Figure 4. Forest plot of the increase in partial pressure of oxygen.

Pulmonary artery pressure

Pulmonary artery pressure before and after treatment was reported in 4 studies,^{26–29} and the magnitude of the decrease in this pressure was analysed in this study. Due to the low heterogeneity among studies ($I^2 = 14\%$, P = 0.32), a fixed-effects model was used for the meta-analysis. The results showed that the decrease in pulmonary artery pressure in the experimental group was lower than in the control group, with a statistically significant difference (mean difference = -11.79, 95% confidence interval: -14.85 to - 8.73, Z-score = 7.56, P < 0.001) as shown in Figure 3.

Partial pressure of oxygen

The partial pressure of oxygen before and after treatment was reported in 3 studies,^{28–30} and the magnitude of the decrease in the partial pressure of oxygen was analysed in this study. Due to the high heterogeneity among the studies ($I^2 = 86\%$, P = 0.0009), a random-effects model was used for the meta-analysis. The results showed that the increase in partial pressure of oxygen in the experimental group was greater than in the control group, with a statistically significant difference (mean difference = 10.02, 95%)

confidence interval: 5.45–14.58, Z-score = 4.30, P < 0.001) as shown in Figure 4.

Blood oxygen saturation

The blood oxygen saturation before and after treatment was reported in three studies,²⁸⁻³⁰ and the magnitude of the decrease in oxygen saturation was analysed in this study. Due to the heterogeneity among studies ($1^2 = 0\%$, P = 0.74), a fixed-effects model was used for the meta-analysis. The results showed that the increase in the blood oxygen saturation in the experimental group was greater than in the control group, with a statistically significant difference (mean difference = 8.24, 95% confidence interval: 6.32–10.15, Z-score = 8.44, P < 0.001) as shown in Figure 5.

Length of hospital stay

Length of hospital stay was reported in 4 studies.^{2,23–25} Due to the low heterogeneity among studies ($I^2 = 27\%$, P = 0.25), a fixed-effects model was used for the meta-analysis. The results showed that the length of hospital stay in the experimental group was shorter than in the control group, with a statistically significant






Figure 6. Forest plot of length of hospital stay.

difference (mean difference = -1.04, 95% confidence interval: -1.74 to -0.35, Z-score = 2.96, P = 0.003) as shown in Figure 6.

Adverse reactions

The occurrence of adverse reactions after treatment was mentioned in 6 studies.^{2,22-26} Because of the different types of adverse reactions, a combined analysis could not be performed; descriptive analysis was thus performed. Mohamed et al.²² reported that in the experimental group, there was 1 case of bronchopulmonary dysplasia and 1 case of increased airway reactivity, while in the control group, there were 3 cases of neurological diseases, 2 cases of bronchopulmonary dysplasia, and 1 case of increased airway reactivity. Steinhorn et al.² reported 3 cases of anaemia, 3 cases of oedema, and 2 cases of vomiting in the experimental group after treatment and only 1 case of anaemia in the control group. Moreover, Maneenil et al.23 reported 3 cases of bronchopulmonary dysplasia and 3 cases of air leakage syndrome in the experimental group, while in the control group, there were 2 and 4 cases, respectively. Studies by Fatima et al.²⁴ and Farhangdoust et al.²⁵ reported no adverse reactions, such as hypotension, after treatment with bosentan. Vijay Kumar et al.²⁶ found that 2 cases in the experimental group had abnormal liver function after treatment with bosentan, while no adverse reactions such as abnormal liver function were found in the control group.

Sensitivity analysis

Sensitivity analysis was conducted on the study outcomes by omitting individual literature studies systematically, and the results were consistent with those before this process (see Table 2 for detailed results).

Discussion

Newborns typically do not have reduced pulmonary vascular resistance due to various risk factors after birth but may suffer from persistent pulmonary hypertension, which poses a serious threat to their lives.³¹ At present, high-frequency ventilation and inhaled nitric oxide are the preferred methods in the treatment of neonatal persistent pulmonary hypertension, but these approaches do not yield satisfactory results. Therefore, there is an urgent need to explore more effective treatments.^{32,33} Bosentan is an endothelin receptor antagonist that induces potent affinity between endothelinA and endothelinB receptors. It can significantly reduce pulmonary vascular resistance and increase cardiac output, thereby improving the symptoms of shortness of breath and cyanotic lips in newborns.³⁴ However, no clear conclusion has been reached on the efficacy and safety of bosentan in the treatment of persistent pulmonary hypertension of the newborn. To this end, we systematically searched the literature on bosentan use in the treatment of persistent pulmonary hypertension of the newborn and conducted a metaanalysis to provide evidence-based results for clinical treatment.

The analysis results showed that the treatment failure rate of the experimental group was lower than that of the control group, while the decrease in pulmonary artery pressure was greater than in the control group. Moreover, the increase in partial pressure of oxygen and blood oxygen saturation in the experimental group was greater than in the control group, and the length of hospital stay was shorter than in the control group. These results are consistent with the results of Goissen et al.³⁵ and Nakwan et al.³⁶ In addition, Radicioni et al.³⁷ reported the improvement of pulmonary artery pressure and blood oxygen saturation in a 28-week-old premature infant with persistent pulmonary hypertension of the newborn who received bosentan treatment. It is speculated that bosentan is effective in newborns with persistent pulmonary hypertension of the newborn and may be independent of gestational age. Bosentan can simultaneously combine with endothelinA and endothelinB to cause a decrease in systolic function and an increase in diastolic function (mediated by the two receptors), thereby achieving the dilation of pulmonary blood vessels, a reduction in pulmonary artery pressure, and oxygenation amelioration. Given that the studies included in this meta-analysis involved small sample sizes, and the samples in most studies comprised full-term infants, more

	Before ex	clusion	After excl	usion
Outcome indicators	RR/MD	Р	RR/MD	Р
Treatment failure rate	0.25ª	<0.001	0.20~0.31 ^a	<0.001~0.005
Pulmonary artery pressure	- 11.79 ^b	<0.001	- 13.23~-10.99 ^b	<0.001
Partial pressure of oxygen	- 10.02 ^b	<0.001	- 9.08~-12.14 ^b	<0.001
Oxygen saturation of blood	8.24 ^b	<0.001	7.84 ~ 9.32 ^b	<0.001
Length of stay	- 1.04 ^b	0.003	- 2.05~-0.92 ^b	<0.001

Table 2. Sensitivity analysis of various indicators

randomised controlled trials are needed to further evaluate and verify this conclusion in the future.

In a stratified analysis of the effects of treatment regimen, study region and drug dose on the efficacy of bosentan, the treatment failure rate of bosentan only or combined with other drugs in the experimental group, and that of bosentan at home or abroad, was lower than in the control group, and the reduction of pulmonary artery pressure was greater than that of the control group. The results were the same as before stratification and also consistent with the results of the retrospective study conducted by Maneenil et al.²³ on 40 newborns with persistent pulmonary hypertension of the newborn. It is concluded that bosentan only or as an adjuvant therapy is effective in newborns with persistent pulmonary hypertension of the newborn.

We conducted a sensitivity analysis on the included studies and the results indicated no impact, suggesting the reliability of the above-noted conclusion. When bosentan is expressed on vascular smooth muscle cells throughout the body, adverse reactions such as hypotension, abnormal liver function, and liver failure may occur.⁴ Drug-induced liver injury is the most common adverse reaction of Bosentan in the treatment of adult pulmonary arterial hypertension.³⁸ In this meta-analysis, 6 studies mentioned adverse reactions, mainly abnormal liver function, anaemia and oedema. Anaemia and oedema may be attributed to bosentan's inhibition of ET protection of red blood cells and its natriuretic effect.³⁹

Our findings are consistent with previous studies that suggested bosentan may have a beneficial effect on persistent pulmonary hypertension of the newborn by reducing pulmonary vascular resistance, improving oxygenation and preventing the development of chronic lung disease.^{2,23} However, our findings also contrast other studies that failed to demonstrate any additive effect of bosentan alongside inhaled NO or other therapies.^{24,25} Moreover, our findings differ from those of Radicioni et al.³⁷ and Maneenil et al.²³, who reported transient hypotension during treatment with bosentan. These discrepancies may be due to several sources of heterogeneity among the studies, such as the differences in study design (randomised controlled trials versus retrospective studies), population characteristics (term versus preterm infants, the severity of persistent pulmonary hypertension of the newborn), intervention methods (bosentan only versus Bosentan combined with other drugs), outcome measurements pulmonary artery pressure versus pulmonary vascular resistance versus oxygenation index, and follow-up duration (3 versus 14 days).

We performed subgroup analysis and meta-regression to explore the impact of these factors on the efficacy and safety of bosentan for patients with persistent pulmonary hypertension of the newborn. However, due to the limited number and quality of the included studies, we could not account for all the potential sources of heterogeneity or adjust for confounding variables. Therefore, our results should be interpreted with caution and further studies with larger and more homogeneous samples are needed to confirm our results.

To our knowledge, this is the first meta-analysis that systematically assessed the efficacy and safety of bosentan for persistent pulmonary hypertension of the newborn in newborns. Our meta-analysis has several strengths, including a comprehensive literature search, a rigorous quality assessment, a sensitivity analysis, and a publication bias assessment. However, our meta-analysis also has limitations that should be acknowledged. First, the number and quality of the included studies were relatively low, which may affect the reliability and generalisability of our results. Second, the dose and duration of bosentan treatment varied among the included studies, which may introduce heterogeneity and confounding factors. Third, some outcome indicators, such as pulmonary vascular resistance, oxygenation index, and alveolar-arterial oxygen gradient, were not reported in most of the included studies, which may limit the comprehensiveness and comparability of our analysis. Fourth, we did not perform subgroup analysis or meta-regression to explore the potential sources of heterogeneity or the effect of moderators such as age, weight, gestational age, severity of persistent pulmonary hypertension of the newborn, or type and dose of other drugs used in the control group. Fifth, we did not assess the longterm outcomes or the cost-effectiveness of bosentan treatment for patients with persistent pulmonary hypertension of the newborn.

Conclusion

To sum up, current evidence shows that when treating newborns with persistent pulmonary hypertension of the newborn, bosentan only or as an adjuvant therapy can reduce the treatment failure rate, pulmonary artery pressure, and length of hospital stay, and increase partial pressure of oxygen and blood oxygen saturation. However, when using bosentan for treatment, liver function should be monitored, and attention should be paid to the occurrence of other adverse reactions. Clinically, more large-scale and high-quality randomised controlled trials are needed for further verification to provide a more reliable evidence-based framework for the treatment of persistent pulmonary hypertension of the newborn.

Data availability. All data generated or analysed during this study are included in this published article.

Acknowledgements. None.

Author contribution. Gao N and Lv YY conceived of the study and designed it. Cui YB and Wang PC participated in the data collection. He X helped with the data analysis. All authors took part in drafting and revising the manuscript. All authors read and approved the final manuscript.

Funding. None.

Competing interests. None.

Ethics approval. An ethics approval and consent to participate statement is not applicable because this study is based exclusively on published literature.

References

- Abman SH, Kinsella JP, Rosenzweig EB, et al. Implications of the U.S. food and drug administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension. Am J Respir Crit Care Med 2013; 187: 572–575.
- Steinhorn RH, Fineman J, Kusic-Pajic A, et al. Bosentan as adjunctive therapy for persistent pulmonary hypertension of the newborn: results of the randomized multicenter placebo-controlled exploratory trial. J Pediatr 2016; 177: 90–96.e3.
- Mourani PM, Sontag MK, Younoszai A, et al. Early pulmonary vascular disease in preterm infants at risk for bronchopulmonary dysplasia. Am J Respir Crit Care Med 2015; 191: 87–95.
- Kinsella JP, McQueston JA, Rosenberg AA, Abman SH. Hemodynamic effects of exogenous nitric oxide in ovine transitional pulmonary circulation. Am J Physiol 1992; 263: H875–H880.
- Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732–1739.
- Mourani PM, Ivy DD, Rosenberg AA, Fagan TE, Abman SH. Left ventricular diastolic dysfunction in bronchopulmonary dysplasia. J Pediatr 2008; 152: 291–293.
- Mourani PM, Sontag MK, Ivy DD, Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 2009; 154: 379–384.e3842.
- Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebocontrolled study. Circulation 2006; 114: 48–54.
- Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010–3019.
- Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 2012; 125: 324–334.
- Bassler D, Choong K, McNamara P, Kirpalani H. Neonatal persistent pulmonary hypertension treated with milrinone: four case reports. Biol Neonate 2006; 89: 1–5.
- Barrington KJ, Finer NN. Inhaled nitric oxide for preterm infants: a systematic review. Pediatrics 2007; 120: 1088–1099.
- Chester M, Seedorf G, Tourneux P, et al. Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2011; 301: L755–L764.
- Kinsella JP, Cutter GR, Walsh WF, et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med 2006; 355: 354–364.
- Kinsella JP, Ivy DD, Abman SH. Pulmonary vasodilator therapy in congenital diaphragmatic hernia: acute, late, and chronic pulmonary hypertension. Semin Perinatol 2005; 29: 123–128.
- Stocker C, Penny DJ, Brizard CP, Cochrane AD, Soto R, Shekerdemian LS. Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. Intensive Care Med 2003; 29: 1996–2003.
- Kawut SM, Taichman DB, Ahya VN, et al. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 2005; 11: 1107–1111.
- Ramani GV, Park MH. Pharmacotherapy for pulmonary arterial hypertension. Heart Fail Clin 2012; 8: 385–402.
- Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension: guidelines from the American heart association and American thoracic society. Circulation 2015; 132: 2037–2099.

- Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions:version 5.1.0 (updated February). The Cochrane Collaboration, 2011. http://www.cochrane-handbook.org.
- Wells A, Shea B, O'Connell D, et al. Thenewcastle-ottawa scale (NOS) for assessing the quality of nonrandomisedstudies in meta-analyses. [EB/OL]. (2012-06-15)[2014-01-13]. http://www.ohri.ca/programs/clinical_epide miology/oxford.htm.
- Mohamed WA, Ismail M. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn. J Perinatol 2012; 32: 608–613.
- Maneenil G, Thatrimontrichai A, Janjindamai W, et al. Effect of bosentan therapy in persistent pulmonary hypertension of the newborn. Pediatr Neonatol 2018; 59: 58–64.
- Fatima N, Arshad S, Quddusi AI, et al. Comparison of the efficacy of sildenafil alone versus sildenafil plus bosentan in newborns with persistent pulmonary hypertension. J Ayub Med Coll Abbottabad 2018; 30: 333–336.
- Farhangdoust S, Mehralizadeh S, Bordbar A. Comparison of the effects of bosentan and sildenafil in the treatment of persistent pulmonary arterial hypertension in infants. J Clin Neonatol 2020; 9: 249–254.
- 26. Vijay Kumar JR, Natraj Setty HS, Jayaranganath M, et al. Efficacy, safety and tolerability of bosentan as an adjuvant to sildenafil and sildenafil alone in persistant pulmonary hypertension of newborn (PPHN). Interv Med Appl Sci 20216; 11: 216–220.
- Wang WL, Sun YJ, Pi YX. Therapeutic effect of bosentan and levocarnitine combined with sildenafil on pulmonary hypertension of the newborn. Hainan Med J 2019; 30: 2390–2393.
- Li GH, Bai B. Efficacy and safety of bosentan combined with milrinone in the treatment of persistent pulmonary hypertension of the newborn. J Med Theory Pract 2020; 33: 111–112.
- Li K, Bai B. Efficacy and safety of bosentan combined with milrinone in the treatment of persistent pulmonary hypertension of the newborn. Med Forum 2021; 25: 53–54.
- Wang SS, Kuang ML, Zuo etal XX. Effects of bosentan combined with treprostinil on red blood cell distribution width and serum melatonin in neonates with persistent pulmonary hypertension. J Pediatr Pharm 2021; 27: 1–3.
- Pan YY, Sun YC, Zhao CF, et al. Clinical observation of bosentan in the treatment of infants with congenital heart disease combined with pulmonary hypertension. J Shandong University 2016; 54: 56–57.
- Qian AM, Jiao FF. Clinical observation of milrinone in the treatment of persistent pulmonary hypertension of newborn. China Pharm 2016; 27: 4993–4994,4995.
- 33. Li XY, Shen MP, Gong HM, et al. Observation on the effect of highfrequency oscillatory ventilation combined with milrinone on persistent pulmonary hypertension of the newborn. Maternal Child Health Care China 2015; 30: 3096–3098.
- Zhang DZ, Zhang XW, Chen HY, et al. Long-term outcome of bosentan therapy in patients with pulmonary arterial hypertension associated with congenital heart diseases. Clin J Med Officers 2019; 47: 1073–1075,1080.
- 35. Goissen C, Ghyselen L, Tourneux P, et al. Persistent pulmonary hypertension of the newborn with transposition of the great arteries: successful treatment with bosentan. Eur J Pediatr 2008; 167: 437–440.
- Nakwan N, Choksuchat D, Saksawad R, et al. Successful treatment of persistent pulmonary hypertension of the newborn with bosentan. Acta Paediatr 2009; 98: 1683–1685.
- Radicioni M, Bruni A, Camerini P. Combination therapy for lifethreatening pulmonary hypertension in a premature infant: first report on bosentan use. Eur J Pediatr 2011; 170: 1075–1078.
- Humbert M, Segal ES, Kiely DG, et al. Results of european post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007; 30: 338–344.
- 39. Wolf D, Tseng N, Seedorf G, et al. Endothelin-1 decreases endothelial PPARγ signaling and impairs angiogenesis after chronic intrauterine pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2014; 306: L361–L371.